Detalles de la búsqueda
1.
High-energy, high-fat lifestyle challenges an Arctic apex predator, the polar bear.
Science
; 359(6375): 568-572, 2018 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29420288
2.
The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.
Aliment Pharmacol Ther
; 33(3): 366-77, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21118280
3.
The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor.
Aliment Pharmacol Ther
; 31(9): 1001-11, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20180789
4.
Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.
Aliment Pharmacol Ther
; 29(8): 824-33, 2009 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19243357
5.
Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
Aliment Pharmacol Ther
; 29(7): 742-54, 2009 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19210298
6.
Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.
Aliment Pharmacol Ther
; 29(7): 731-41, 2009 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19183157
7.
Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
Aliment Pharmacol Ther
; 29(12): 1261-72, 2009 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19392864
8.
Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
Aliment Pharmacol Ther
; 30(9): 895-907, 2009 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19681809
9.
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Aliment Pharmacol Ther
; 30(10): 1010-21, 2009 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19735233
10.
An open, randomised, parallel group study of lactulose versus ispaghula in the treatment of chronic constipation in adults.
Br J Clin Pract
; 45(1): 28-30, 1991.
Artículo
en Inglés
| MEDLINE | ID: mdl-1931536
11.
A comparison of mebeverine with high-fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomised, parallel group study.
Br J Clin Pract
; 44(11): 461-6, 1990 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-2177997
12.
A randomised, double-blind study of mebeverine versus dicyclomine in the treatment of functional abdominal pain in young adults.
Br J Clin Pract
; 44(5): 176-9, 1990 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-2202405
Resultados
1 -
12
de 12
1
Próxima >
>>